Exposure-response analyses of pemigatinib in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 rearrangement [0.03%]
Pemigatinib组暴露反应分析：携带FGFR1重排的髓样/淋巴组织肿瘤患者的疗效和安全性评估
Xiaohua Gong,Ayman Akil,Boris Grinshpun et al.
Xiaohua Gong et al.
Pemigatinib is a selective, potent, orally administered inhibitor of fibroblast growth factor receptor (FGFR)1-3 with antitumor activity in multiple solid tumors. Pemigatinib is used to treat adults with previously treated metastatic or sur...
Neural networks for the prediction of bacterial and fungal infections: current evidence and implications [0.03%]
预测细菌和真菌感染的人工神经网络：现有证据及其影响
Cristina Marelli,Daniele Roberto Giacobbe,Alessandro Limongelli et al.
Cristina Marelli et al.
In the present narrative review, we discuss the use of artificial neural networks (ANNs) for predicting bacterial and fungal infections based on commonly available clinical and laboratory data, focusing on promises and challenges of these m...
Immunotherapy in mesothelioma - systematic review and meta-analysis of immunotherapy impact on OS and its correlation with PFS and ORR [0.03%]
免疫疗法治疗间皮瘤的系统评价和Meta分析：对总生存期的影响及其与无进展生存期和客观缓解率的相关性
Marko Skelin,Kaja Matić,Andrea Anić-Matić et al.
Marko Skelin et al.
Mesothelioma has a poor prognosis, with a 5-year overall survival (OS) rate less than 5%. Immunotherapy has been proven as a promising alternative to platinum-based therapies in first-line treatment. Our systematic literature search include...
Application of dihydropyrimidine dehydrogenase deficiency testing for the prevention of fluoropyrimidine toxicity: a real-world experience in a Southern Italy cancer center [0.03%]
二氢嘧啶脱氢酶缺乏检测预防氟尿嘧啶类药物毒性的应用：意大利南部一家癌症中心的真实世界经验
Gabriella Bianchino,Alessandra Perrone,Alessandro Sgambato et al.
Gabriella Bianchino et al.
Fluoropyrimidines (FPs) are antineoplastic agents used for the treatment of various solid tumors, especially gastrointestinal cancers. Patients with variations in dihydropyrimidine dehydrogenase gene (DPYD), which can determine the partial ...
Liposome-assisted combination chemotherapy improves the anti-proliferation and anti-angiogenesis response of cisplatin in breast cancer; experimental and computational study [0.03%]
脂质体增强的联合化疗可改善顺铂在乳腺癌中的抗增殖和抗血管生成反应：实验和计算研究
Nasim Valinezhadi,Gholamreza Dehghan,Mohammad Yaghoubzad-Maleki et al.
Nasim Valinezhadi et al.
AbstractCombination chemotherapy using liposomes offers a promising approach to overcome chemotherapy resistance and minimize side effects in breast cancer treatment. This study explores the synergistic effects of all-trans-retinoic acid (A...
Single versus two doses of palonosetron for prevention of chemotherapy-induced nausea and vomiting in children: a double-blind placebo controlled randomized study [0.03%]
帕洛诺司琼单次或2次剂量用于防治儿童化疗引起的恶心呕吐：一项双盲、安慰剂对照的随机研究
Sandeep Jain,Neeraj Teotia,Payal Malhotra et al.
Sandeep Jain et al.
This single-centre, double-blinded, placebo-controlled randomized study aimed to assess the efficacy of single versus two doses of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Children receiving multipl...
Andrea Duminuco,Giuseppe Novello,Elisa Mauro et al.
Andrea Duminuco et al.
Chemotherapy extravasation, the unintended leakage of cytotoxic drugs into surrounding tissues, is a significant complication in oncological treatments, potentially leading to severe tissue damage and long-term consequences. This review exp...
Association between trastuzumab treatment interruption and survival in HER2-positive metastatic breast cancer patients: a retrospective study [0.03%]
曲妥珠单抗治疗中断与HER2阳性转移性乳腺癌患者生存的关系：一项回顾性研究
Ludmila Andrade Alves Ferreira,Mário Jorge Sobreira da Silva,Patricia Ribeiro Portella de Araújo et al.
Ludmila Andrade Alves Ferreira et al.
This retrospective study analyzed the effect of trastuzumab treatment interruption on overall survival (OS) and progression-free survival (PFS) within two years after diagnosis in women with HER2-positive metastatic breast cancer. Sociodemo...
Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer [0.03%]
PD-1 / PD-L1抑制剂对晚期非小细胞肺癌不良体能状态患者临床疗效的分析
Junji Koyama,Masahiro Morise,Ichidai Tanaka et al.
Junji Koyama et al.
The benefit of programmed cell death protein-1 (PD-1)/programmed cell death protein ligand-1 (PD-L1) inhibitors remains unclear in non-small cell lung cancer (NSCLC) patients with poor performance status (PS). In the current multi-centre re...
Concurrent inhibition of FLT3 and sphingosine kinase-1 triggers synergistic cytotoxicity in midostaurin resistant FLT3-ITD positive acute myeloid leukemia cells via blocking FLT3/STAT5A signaling to induce apoptosis [0.03%]
FLT3和鞘氨醇激酶-1的联合作用触发对midostaurin耐药的FLT3-ITD阳性急性髓系白血病细胞的协同毒性：通过阻断FLT3/STAT5A信号通路诱导凋亡机制
Melisa Tecik,Aysun Adan
Melisa Tecik
The FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) is one of the most frequent mutations observed in acute myeloid leukemia (AML) which contributes to disease progression and unfavorable prognosis. Midostaurin, a small FL...